[Congressional Record Volume 167, Number 92 (Wednesday, May 26, 2021)]
[Senate]
[Pages S3512-S3513]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]

  SA 2034. Ms. WARREN (for herself and Mr. Rubio) submitted an 
amendment intended to be proposed to amendment SA 1502 proposed by Mr. 
Schumer to the bill S. 1260, to establish a new Directorate for 
Technology and Innovation in the National Science Foundation, to 
establish a regional technology hub program, to require a strategy and 
report on economic security, science, research, innovation, 
manufacturing, and job creation, to establish a critical supply chain 
resiliency program, and for other purposes; which was ordered to lie on 
the table; as follows:

        At the end of title III of division E, add the following:

     SEC. 5311. REPORT ON FOREIGN INVESTMENT FROM THE PEOPLE'S 
                   REPUBLIC OF CHINA IN PHARMACEUTICAL INDUSTRY.

       (a) In General.--Not later than one year after the date of 
     the enactment of this Act,

[[Page S3513]]

     and annually thereafter, the Federal Trade Commission, in 
     consultation with the Secretary of Commerce, shall submit to 
     the appropriate congressional committees, the Secretary of 
     Health and Human Services, the Committee on Foreign 
     Investment in the United States, and the Commissioner of Food 
     and Drugs, a report on foreign investment from the People's 
     Republic of China in the pharmaceutical industry of the 
     United States.
       (b) Elements.--The report required by subsection (a) shall 
     include an assessment of--
       (1) the supply chain of the pharmaceutical industry of the 
     United States and the effect of concentration and reliance on 
     manufacturing in the People's Republic of China within that 
     industry;
       (2) the effect of foreign investment from the People's 
     Republic of China in the pharmaceutical industry of the 
     United States on domestic capacity to produce drugs and 
     active and inactive ingredients of drugs; and
       (3) the effect of foreign investment from the People's 
     Republic of China in technologies or other products for 
     sequencing or storage of DNA, including genome and exome 
     analysis, in the United States, including the effect of such 
     investment on the capacity to sequence or store DNA in the 
     United States.
       (c) Authority.--The Federal Trade Commission shall have 
     authority under section 6 of the Federal Trade Commission Act 
     (15 U.S.C. 46) to conduct the studies required to prepare the 
     report required by subsection (a).
       (d) Publication.--The Federal Trade Commission shall 
     publish an unclassified summary of the report required by 
     subsection (a) on a publicly available internet website of 
     the Commission.
       (e) Appropriate Congressional Committees Defined.--In this 
     section, the term ``appropriate congressional committees'' 
     means--
       (1) the Committee on Banking, Housing, and Urban Affairs, 
     the Committee on Health, Education, Labor, and Pensions, the 
     Committee on Armed Services, the Committee on Foreign 
     Relations, the Committee on Commerce, Science, and 
     Transportation, and the Committee on Appropriations of the 
     Senate; and
       (2) the Committee on Financial Services, the Committee on 
     Energy and Commerce, the Committee on Armed Services, the 
     Committee on Foreign Affairs, and the Committee on 
     Appropriations of the House of Representatives.
                                 ______